These observations suggest that the treatment naïve IDH2-mutant AML blasts are highly sensitive to venetoclax in combination with cytarabine and anthracycline chemotherapy, resulting in a high clinical response rate; in contrast, IDH1-mutant AMLs seem to be less sensitive to this treatment [167]. Here, IDH2 is linked to acute myeloid leukemia.